Non-small cell lung cancer nonsquamous · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 265 140 | 28d | — | — | — | — | — |
Cisplatin, Pemetrexed, Durvalumab N/A - protocol | — | R 264 489 | 28d | — | — | — | — | — |
Cisplatin, Pemetrexed, Pembrolizumab Variant #01 | — | R 83 075 | 21d | — | — | — | — | 1 |
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | ~6.1 mo | ~14.2 mo | ~9 | ~R 45 276 PFS proxy · indirect | 7 |
Cisplatin, Pemetrexed, Nivolumab Variant #01 Partial | — | R 1 088 | 21d | — | — | — | — | 1 |
Cisplatin and Pemetrexed Variant #01 | — | R 1 088 | 21d | — | — | — | — | 2 |
Carboplatin and Pemetrexed N/A - secondary systemic drug | — | R 52 | 21d | ~5.1 mo | ~14.9 mo | ~8 | ~R 417 PFS proxy · indirect | 18 |
7 of 7 regimens shown